PROS1 and prostate cancer: Subsequently, Yoneyama et al. presented a study on the application of a specifically glycosylated form of PSA, designated as S23PSA (α2,3-sialylated PSA), as a biomarker for detecting clinically significant prostate cancer in men with elevated PSA levels.